AZN logo

AstraZeneca PLC

AZN
Healthcare|Drug Manufacturers - General|GB
$186.43
-0.42 (-0.22%)
DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23
Next Earnings Report
Feb 9, 2027
EPS est. $2.32 · Revenue est. $16.59B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Feb 27, 2026 (424B2). Possible dilution.

Upcoming Data Readouts (61)

Dec 2026
Est. completion
Asthma
PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults
Dec 2026
Est. completion
P2IgM MGUS
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
Dec 2026
Est. completion
NAPreventable Disease, Vaccine
Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies
Dec 2026
Est. completion
Non-squamous Non-Small Cell Lung Cancer
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
Dec 2026
Est. completion
Heart Diseases
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
Dec 2026
Est. completion
Metastatic Breast Cancer
HER2-positive Metastatic Breast Cancer in Kazakhstan
Jan 2027
Est. completion
P2Extrahepatic Cholangiocarcinoma
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma
Jan 2027
Est. completion
P3Cardiovascular Disease
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
Jan 2027
Est. completion
P1P2Diffuse Large B-Cell Lymphoma
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Feb 2027
Est. completion
P3Lymphoma, Mantle Cell
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Mar 2027
Est. completion
P1P2Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Mar 2027
Est. completion
P1P2Gastric Cancer
Study for AZD4360 in Participants With Advanced Solid Tumours
Apr 2027
Est. completion
P2Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
Jun 2027
Est. completion
P2Non-Small Cell Lung Cancer
Boosting Osimertinib Blood Brain Barrier Penetration
Jun 2027
Est. completion
Severe Asthma
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
Jul 2027
Est. completion
P3Kidney Disease, Chronic
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
Sep 2027
Est. completion
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Oct 2027
Est. completion
P2Non-Small Cell Lung Cancer (NSCLC)
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
Oct 2027
Est. completion
P2HER2-positive Breast Cancer
Basket Study for Oligo-metastatic Breast Cancer
Nov 2027
Est. completion
P3Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Awaiting Results (22)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
P2
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570
Oct 2026
P2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159
Oct 2026
P2
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
NCT07017179
Oct 2026
P1P2
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)
NCT07717840
Sep 2026
P2
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
NCT03668340
Jul 2026
P3
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Jun 2026
P3
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068
Mar 2026
P3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709
Jan 2026
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
NCT05103605
May 2025
P3
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
NCT04191304

Recent Press Releases

AstraZeneca results: 9M and Q3 2026
Oct 30, 2026 · Business Wire

SEC Filings (245)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 2, 20266-KForeign issuer reportDocumentIndex
Nov 2, 20266-KForeign issuer reportDocumentIndex
Oct 30, 20266-KForeign issuer reportDocumentIndex
Oct 27, 20266-KForeign issuer reportDocumentIndex
Oct 22, 20266-KForeign issuer reportDocumentIndex
Oct 5, 20266-KForeign issuer reportDocumentIndex
Oct 2, 20266-KForeign issuer reportDocumentIndex
Oct 1, 20266-KForeign issuer reportDocumentIndex
Oct 1, 20266-KForeign issuer reportDocumentIndex
Sep 29, 20266-KForeign issuer reportDocumentIndex
Sep 23, 20266-KForeign issuer reportDocumentIndex
Sep 21, 20266-KForeign issuer reportDocumentIndex
Sep 21, 20266-KForeign issuer reportDocumentIndex
Sep 18, 20266-KForeign issuer reportDocumentIndex
Sep 15, 20266-KForeign issuer reportDocumentIndex
Sep 15, 20266-KForeign issuer reportDocumentIndex
Sep 14, 20266-KForeign issuer reportDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Aug 27, 20266-KForeign issuer reportDocumentIndex
Aug 25, 20266-KForeign issuer reportDocumentIndex
Aug 19, 20266-KForeign issuer reportDocumentIndex
Aug 17, 20266-KForeign issuer reportDocumentIndex
Aug 17, 20266-KForeign issuer reportDocumentIndex
Aug 17, 20266-KForeign issuer reportDocumentIndex
Aug 3, 20266-KForeign issuer reportDocumentIndex
Aug 3, 20266-KForeign issuer reportDocumentIndex
Jul 31, 20266-KForeign issuer reportDocumentIndex
Jul 27, 20266-KForeign issuer reportDocumentIndex
Jul 27, 20266-KForeign issuer reportDocumentIndex
Jul 27, 20266-KForeign issuer reportDocumentIndex
Jul 23, 20266-KForeign issuer reportDocumentIndex
Jul 14, 20266-KForeign issuer reportDocumentIndex